IFRX - InflaRx N.V.
InflaRx N.V. Logo

IFRX - InflaRx N.V.

https://www.inflarx.de
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

InflaRx NV, a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company is headquartered in Jena, Germany.

52W High
$2.82
52W Low
$0.71
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.45
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
0.50
EV/Revenue (<3 favorable)
297.88
P/S (TTM) (<3 favorable)
686.51
P/B (<3 favorable)
1.68
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
6.38%
Institutions (25–75% balanced)
24.96%
Shares Outstanding
67,747,000
Float
56,941,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
162,830
Gross Profit (TTM)
-4,994,412
EPS (TTM)
-0.85
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-350.91%
ROE (TTM) (>15% strong)
-0.65%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
5.20
Momentum
Bearish momentum
Value
0.1831
Previous
0.2225
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025